NCT05028556View on ClinicalTrials.gov

A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 6, 2021

Primary Completion Date

July 5, 2024

Study Completion Date

September 9, 2024

Conditions

Metastatic or Locally Advanced Solid Tumors

Interventions

DRUG

Cohort 1 of Y101D

Y101D, 1mg/kg, Q2W, intravenous infusion

DRUG

Cohort 2 of Y101D

Y101D, 3mg/kg, Q2W, intravenous infusion

DRUG

Cohort 3 of Y101D

Y101D, 10mg/kg, Q2W, intravenous infusion

DRUG

Cohort 4 of Y101D

Y101D, 20mg/kg, Q2W, intravenous infusion

DRUG

Cohort 5 of Y101D

Y101D, 30mg/kg, Q2W, intravenous infusion

Trial Locations (3)

Unknown

Cancer Prevention Center, Sun Yat-sen University, Guangzhou

Henan Cancer Hospital, Zhengzhou

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Wuhan YZY Biopharma Co., Ltd.

INDUSTRY

NCT05028556 - A Trial of Y101D, a PD-L1/TGF-β Bispecific Antibody, in Patients With Metastatic or Locally Advanced Solid Tumors | Biotech Hunter | Biotech Hunter